Tifacogin

Drug Profile

Tifacogin

Alternative Names: LACI; SC 59735; TFP561; TFPI - Chiron/Pfizer; Tissue factor pathway inhibitor - Chiron/Pfizer

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chiron
  • Developer Novartis
  • Class Antithrombotics; Biological proteins
  • Mechanism of Action Factor Xa inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Community-acquired pneumonia; Reperfusion injury; Septic shock; Thrombosis

Most Recent Events

  • 28 Jan 2009 Development discontinued for Community-acquired pneumonia during 2008
  • 22 Apr 2008 Pharmacodynamics data from a preclinical trial against Escherichia coli infection (related to Community-acquired pneumonia) presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2008)
  • 22 May 2007 Tifacogin is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top